= 912444-00-9 [标题:Reaction Conditions 标题:Co-Encapsulation Of Methylene Blue And Parp-Inhibitor Into Poly(Lactic-Co-Glycolic Acid) Nanoparticles For Enhanced Pdt Of Cancer 作者:Magalhaes,Jessica A.; Et Al 参考文献:Nanomaterials 日期:2021 卷标:11(6)]
= 912444-00-9 [标题:Reaction Conditions 标题:Synthesis Of (R)-Boc-2-Methylproline Via A Memory Of Chirality Cyclization. Application To The Synthesis Of Veliparib,A Poly(Adp-Ribose) Polymerase Inhibitor 作者:Kolaczkowski,Lawrence; Et Al 参考文献:Journal Of Organic Chemistry 日期:2019 卷标:84(8) 页码:4837-4845]
专利号:US-12391691-B2 优先权日:2018-11-16 标题:Synthesis of key intermediate of KRAS G12C inhibitor compound 发明人:PARSONS ANDREW THOMAS; COCHRAN BRIAN MCNEIL; POWAZINIK IV WILLIAM; CAPORINI MARC ANTHONY 权利人:AMGEN INC 摘要:The present invention relates to an improved, efficient, scalable process to prepare intermediate compounds, such as compound 5M, having the structure n nuseful for the synthesis of compounds that target KRAS G12C mutations, such as
专利号:US-2025206736-A1 优先权日:2019-11-14 标题 :Synthesis of kras g12c inhibitor compound 发明人:CORBETT MICHAEL THOMAS; CAILLE SEBASTIEN 权利人:AMGEN INC 摘要:The present disclosure relates to an improved, efficient, scalable process to prepare intermediate compounds, such as 2-isopropyl-4-methylpyridin-3-amine, useful for the synthesis of compounds, such as Compound 9, for the treatment of KRAS G12C mutated cancers.
专利号:US-12043612-B2 优先权日:2020-05-09 标 题 :Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same 发明人:ALLAN LAURA E N; CHEN CHUNGPIN HERMAN; DONG HANQING; GROSSO JOHN A; HASKELL III ROYAL J; LLOYD RHYS; REECE HAYLEY 权利人:ARVINAS OPERATIONS INC 摘要:The present disclosure relates to ultra-pure forms, polymorphs, amorphous forms, and formulations of N-[(1r,4r)-4-(3-chloro-4-cyanophenoxy)cyclohexyl]-6-[4-({4-[2-(2,6-dioxopiperidin-3-yl)-6-fluoro-1,3-dioxo-2,3-dihydro-1H-isoindol-5-yl]piperazin-1-yl}methyl)piperidin-1-yl]pyridazine-3-carboxamide, referred to herein as Compound A:The present disclosure also relates methods of manufacturing and purifying the same, as well as intermediates useful in the synthesis of Compound A. The ultra-pure forms, polymorphs, amorphous forms, and formulations of Compound A can be used as therapeutic agents for the treatment of various diseases and conditions such as cancer.
专利号:US-9993570-B2 优先权日:2014-01-05 标题:Radiolabeled tracers for poly (ADP-ribose) polymerase-1 (PARP-1), methods and uses therefor 发明人:MACH ROBERT; CHU WENHUA; ZHOU DONG; MICHEL LOREN; CHEN DELPHINE 权利人:UNIV WASHINGTON 摘要:Disclosed are PARP-1 inhibitors, which can be 18 F-labeled for use as tracers in positron emission tomographic (PET) imaging. Further disclosed are methods of synthesis. Of the compounds synthesized, 2-[p-(2-Fluoroethoxy)phenyl]-1.3.10-triazatricyclo[6.4.1.0 4,13 ]trideca-2,4(13),5,7-tetraen-9-one (12) had the highest inhibition potency for PARP-1 (IC 50 =6.3 nM). Synthesis of [ 18 F]-12 is disclosed under conventional conditions in high specific activity with 40-50% decay-corrected yield. MicroPET imaging using [ 18 F]-12 in MDA-MB-436 tumor-bearing mice demonstrated accumulation of [ 18 F]-12 in a tumor. Binding, can be blocked by olaparib. The compounds have utility for tumor imaging.
专利号:US-9598418-B2 优先权日:2012-12-31 标 题:Substituted phthalazin-1 (2H)-one derivatives as selective inhibitors of poly (ADP-ribose) polymerase-1 发明人:SRIVASTAVA BRIJESH K; DESAI RANJIT C; PATEL PANKAJ R 权利人:CADILA HEALTHCARE LTD 摘要:The present invention relates to novel compounds of general formula (I), their stereoisomers, regioisomers, tautomeric forms and novel intermediates involved in their synthesis, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates and pharmaceutical compositions containing them. The present invention also relates to a process of preparing novel compounds of general formula (I), their stereoisomers, regioisomers, their tautomeric forms, their pharmaceutically acceptable salts, pharmaceutically acceptable solvates, pharmaceutical compositions containing them, and novel intermediates involved in their synthesis.
专利号:WO-2023143427-A1 优先权日:2022-01-27 标题 :Crystal form of arv-110 and preparation method therefor and use thereof 发明人:SHENG XIAOXIA; SHENG XIAOHONG; CAO YAQING 权利人:HANGZHOU SOLIPHARMA CO LTD 摘要:The present application relates to the field of drug synthesis, in particular to a crystal form of ARV-110 and a preparation method therefor and a use thereof. The crystal form of the ARV-110 at least has one of the following improved characteristics: the stability is good, the hygroscopicity is low, the solubility is good, the melting point is high, stable storage can be achieved, crystal transformation of a drug in a development process and storage is avoided, the preparation method is simple and reliable, and great development values are achieved.
1: George RR, Thomas R, Davice A, Mathew MS. Veliparib for the treatment of solid malignancies. J Oncol Pharm Pract. 2022 Jun;28(4):924-934. doi: 10.1177/10781552221073990. Epub 2022 Jan 17. 33(4):384-394. doi: 10.1016/j.annonc.2022.01.009. Epub 2022 Jan 31. 42(3):260-273. doi: 10.1080/07357907.2024.2338128. Epub 2024 Apr 8. 15(17):1975-1987. doi: 10.2217/fon-2018-0883. Epub 2019 May 10. 19(4):497-509. doi: 10.1016/S1470-2045(18)30111-6. Epub 2018 Feb 28. 381(25):2403-2415. doi: 10.1056/NEJMoa1909707. Epub 2019 Sep 28. 7: Boussios S, Karihtala P, Moschetta M, Abson C, Karathanasi A, Zakynthinakis- Kyriakou N, Ryan JE, Sheriff M, Rassy E, Pavlidis N. Veliparib in ovarian cancer: a new synthetically lethal therapeutic approach. Invest New Drugs. 2020 Feb;38(1):181-193. doi: 10.1007/s10637-019-00867-4. Epub 2019 Oct 24. 10(12):1637-1644. doi: 10.1001/jamaoncol.2024.4361. Erratum in: JAMA Oncol. 2024 Dec 1;10(12):1736. doi: 10.1001/jamaoncol.2024.6238. Erratum in: JAMA Oncol. 2025 Apr 1;11(4):435. doi: 10.1001/jamaoncol.2025.0254. 9: O'Reilly EM, Lee JW, Zalupski M, Capanu M, Park J, Golan T, Tahover E, Lowery MA, Chou JF, Sahai V, Brenner R, Kindler HL, Yu KH, Zervoudakis A, Vemuri S, Stadler ZK, Do RKG, Dhani N, Chen AP, Kelsen DP. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation. J Clin Oncol. 2020 May 1;38(13):1378-1388. doi: 10.1200/JCO.19.02931. Epub 2020 Jan 24.
合成参考文献
参考文献:10.4161/cbt.7.6.5933 摘要:Liu X, Luo X, Shi Y, Zhu GD, Penning T, Giranda VL, Luo Y. Poly (ADP-ribose) polymerase activity regulates apoptosis in HeLa cells after alkylating DNA damage. Cancer Biol Ther. 2008 Jun;7(6):934–41. doi: 10.4161/cbt.7.6.5933. 参考文献:10.1007/s10555-008-9140-0 摘要:Dhani N, Siu LL. Clinical trials and biomarker development with molecularly targeted agents and radiotherapy. Cancer Metastasis Rev. 2008 Sep;27(3):339–49. doi: 10.1007/s10555-008-9140-0. 参考文献:10.1158/0008-5472.can-11-0814 摘要:Huehls AM, Wagner JM, Huntoon CJ, Geng L, Erlichman C, Patel AG, Kaufmann SH, Karnitz LM. Poly(ADP-Ribose) polymerase inhibition synergizes with 5-fluorodeoxyuridine but not 5-fluorouracil in ovarian cancer cells. Cancer Res. 2011 Jul 15;71(14):4944–54. 参考文献:10.3892/ijo.2012.1740 摘要:Feng X, Koh DW. Inhibition of poly(ADP-ribose) polymerase-1 or poly(ADP‑ribose) glycohydrolase individually, but not in combination, leads to improved chemotherapeutic efficacy in HeLa cells. Int J Oncol. 2013 Feb;42(2):749–56. 参考文献:10.1007/s00280-014-2486-9 摘要:Plummer R, Stephens P, Aissat-Daudigny L, Cambois A, Moachon G, Brown PD, Campone M. Phase 1 dose-escalation study of the PARP inhibitor CEP-9722 as monotherapy or in combination with temozolomide in patients with solid tumors. Cancer Chemotherapy and Pharmacology. 2014 Jun 01;74(2):257–65. doi: 10.1007/s00280-014-2486-9.